PDCD1 and neoplasm: An interesting observation suggested that the use of the chemo-immunotherapeutic approach, combining the topo-active drug teniposide with anti-PD1 antibodies, shows promise for enhanced antitumor efficacy in mouse tumor models, with implications for the STING pathway [214,215].